CA2424884C - Substituted (e)-styryl benzylsulfones for treating proliferative disorders - Google Patents
Substituted (e)-styryl benzylsulfones for treating proliferative disorders Download PDFInfo
- Publication number
- CA2424884C CA2424884C CA002424884A CA2424884A CA2424884C CA 2424884 C CA2424884 C CA 2424884C CA 002424884 A CA002424884 A CA 002424884A CA 2424884 A CA2424884 A CA 2424884A CA 2424884 C CA2424884 C CA 2424884C
- Authority
- CA
- Canada
- Prior art keywords
- alkoxy
- group
- amino
- halogen
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000002062 proliferating effect Effects 0.000 title claims description 16
- MRTIWTGAGMZREP-VAWYXSNFSA-N [(e)-2-phenylethenyl]sulfonylmethylbenzene Chemical class C=1C=CC=CC=1/C=C/S(=O)(=O)CC1=CC=CC=C1 MRTIWTGAGMZREP-VAWYXSNFSA-N 0.000 title abstract description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 97
- -1 for example Substances 0.000 claims abstract description 62
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 29
- 150000003839 salts Chemical class 0.000 claims abstract description 28
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 26
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims abstract description 24
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims abstract description 23
- 150000002367 halogens Chemical group 0.000 claims abstract description 20
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract description 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 201000011510 cancer Diseases 0.000 claims description 18
- 210000004881 tumor cell Anatomy 0.000 claims description 17
- 208000035475 disorder Diseases 0.000 claims description 14
- 206010016654 Fibrosis Diseases 0.000 claims description 9
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 230000006907 apoptotic process Effects 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- IETYYZGMBLLKGJ-KAVGSWPWSA-N 2,4-dichloro-1-[(e)-1-[(e)-1-(2,4-dichlorophenyl)-3-(2-nitrophenyl)prop-2-enyl]sulfonyl-3-(2-nitrophenyl)prop-2-enyl]benzene Chemical compound [O-][N+](=O)C1=CC=CC=C1\C=C\C(S(=O)(=O)C(\C=C\C=1C(=CC=CC=1)[N+]([O-])=O)C=1C(=CC(Cl)=CC=1)Cl)C1=CC=C(Cl)C=C1Cl IETYYZGMBLLKGJ-KAVGSWPWSA-N 0.000 claims description 6
- 210000000481 breast Anatomy 0.000 claims description 6
- 230000004761 fibrosis Effects 0.000 claims description 5
- 210000004291 uterus Anatomy 0.000 claims description 5
- GKXBWKLPVJUONS-MBALSZOMSA-N 2-[(e)-3-[(e)-3-(2,6-dimethoxyphenyl)-1-(2-methoxyphenyl)prop-2-enyl]sulfonyl-3-(2-methoxyphenyl)prop-1-enyl]-1,3-dimethoxybenzene Chemical compound COC1=CC=CC=C1C(S(=O)(=O)C(\C=C\C=1C(=CC=CC=1OC)OC)C=1C(=CC=CC=1)OC)\C=C\C1=C(OC)C=CC=C1OC GKXBWKLPVJUONS-MBALSZOMSA-N 0.000 claims description 4
- 210000000988 bone and bone Anatomy 0.000 claims description 4
- 210000004556 brain Anatomy 0.000 claims description 4
- 210000001072 colon Anatomy 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 210000002307 prostate Anatomy 0.000 claims description 4
- UOSXHFFPGRNSGK-FNCQTZNRSA-N 2,4-dichloro-1-[(e)-1-[(e)-1-(2,4-dichlorophenyl)-3-(3-nitrophenyl)prop-2-enyl]sulfonyl-3-(3-nitrophenyl)prop-2-enyl]benzene Chemical compound [O-][N+](=O)C1=CC=CC(\C=C\C(C=2C(=CC(Cl)=CC=2)Cl)S(=O)(=O)C(\C=C\C=2C=C(C=CC=2)[N+]([O-])=O)C=2C(=CC(Cl)=CC=2)Cl)=C1 UOSXHFFPGRNSGK-FNCQTZNRSA-N 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 208000000571 Fibrocystic breast disease Diseases 0.000 claims description 3
- 208000009905 Neurofibromatoses Diseases 0.000 claims description 3
- 208000011803 breast fibrocystic disease Diseases 0.000 claims description 3
- 210000003679 cervix uteri Anatomy 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 claims description 3
- 230000007882 cirrhosis Effects 0.000 claims description 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 3
- 210000003238 esophagus Anatomy 0.000 claims description 3
- 210000000232 gallbladder Anatomy 0.000 claims description 3
- 208000011379 keloid formation Diseases 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 210000004324 lymphatic system Anatomy 0.000 claims description 3
- 201000004931 neurofibromatosis Diseases 0.000 claims description 3
- 210000001672 ovary Anatomy 0.000 claims description 3
- 230000000750 progressive effect Effects 0.000 claims description 3
- 210000000664 rectum Anatomy 0.000 claims description 3
- 208000037803 restenosis Diseases 0.000 claims description 3
- 201000000306 sarcoidosis Diseases 0.000 claims description 3
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 claims description 3
- 210000003491 skin Anatomy 0.000 claims description 3
- 210000002784 stomach Anatomy 0.000 claims description 3
- 210000001550 testis Anatomy 0.000 claims description 3
- 210000001215 vagina Anatomy 0.000 claims description 3
- 230000002792 vascular Effects 0.000 claims description 3
- BSTLUVRKBCKXGT-ASIDMNOUSA-N 1-ethoxy-4-[(e)-3-[(e)-3-(4-ethoxy-3-methoxyphenyl)-1-(4-methoxyphenyl)prop-2-enyl]sulfonyl-3-(4-methoxyphenyl)prop-1-enyl]-2-methoxybenzene Chemical compound C1=C(OC)C(OCC)=CC=C1\C=C\C(S(=O)(=O)C(\C=C\C=1C=C(OC)C(OCC)=CC=1)C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BSTLUVRKBCKXGT-ASIDMNOUSA-N 0.000 claims description 2
- ZSDWWBXFYUNHQD-FDOALMFVSA-N 5-[(e)-3-(4-chlorophenyl)-3-[(e)-1-(4-chlorophenyl)-3-(3-hydroxy-4-nitrophenyl)prop-2-enyl]sulfonylprop-1-enyl]-2-nitrophenol Chemical compound C1=C([N+]([O-])=O)C(O)=CC(\C=C\C(C=2C=CC(Cl)=CC=2)S(=O)(=O)C(\C=C\C=2C=C(O)C(=CC=2)[N+]([O-])=O)C=2C=CC(Cl)=CC=2)=C1 ZSDWWBXFYUNHQD-FDOALMFVSA-N 0.000 claims description 2
- 208000016738 bone Paget disease Diseases 0.000 claims description 2
- 230000002489 hematologic effect Effects 0.000 claims description 2
- 230000009826 neoplastic cell growth Effects 0.000 claims description 2
- 210000004100 adrenal gland Anatomy 0.000 claims 2
- 210000001508 eye Anatomy 0.000 claims 2
- KKNYJLLYAAMKKN-UHFFFAOYSA-N [N+](=O)([O-])C1=CC=C(C=CC(C2=C(C=CC(=C2)[N+](=O)[O-])OC)S(=O)(=O)C(C2=C(C=CC(=C2)[N+](=O)[O-])OC)C=CC2=CC=C(C=C2)[N+](=O)[O-])C=C1 Chemical compound [N+](=O)([O-])C1=CC=C(C=CC(C2=C(C=CC(=C2)[N+](=O)[O-])OC)S(=O)(=O)C(C2=C(C=CC(=C2)[N+](=O)[O-])OC)C=CC2=CC=C(C=C2)[N+](=O)[O-])C=C1 KKNYJLLYAAMKKN-UHFFFAOYSA-N 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 9
- 239000001257 hydrogen Chemical group 0.000 abstract description 9
- 239000003795 chemical substances by application Substances 0.000 abstract description 7
- 150000002431 hydrogen Chemical group 0.000 abstract description 5
- 230000001028 anti-proliverative effect Effects 0.000 abstract description 4
- 239000002246 antineoplastic agent Substances 0.000 abstract description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract description 2
- 238000000034 method Methods 0.000 description 52
- 239000000243 solution Substances 0.000 description 45
- 210000004027 cell Anatomy 0.000 description 40
- 230000008018 melting Effects 0.000 description 37
- 238000002844 melting Methods 0.000 description 37
- MXXQOAGTJXSSCB-UHFFFAOYSA-N 2-[(4-methoxyphenyl)methylsulfonyl]acetic acid Chemical compound COC1=CC=C(CS(=O)(=O)CC(O)=O)C=C1 MXXQOAGTJXSSCB-UHFFFAOYSA-N 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 10
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 10
- 102000043136 MAP kinase family Human genes 0.000 description 10
- 108091054455 MAP kinase family Proteins 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 8
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000013543 active substance Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- HPWAJMXOEYIERK-UHFFFAOYSA-N 2-benzylsulfonylacetic acid Chemical class OC(=O)CS(=O)(=O)CC1=CC=CC=C1 HPWAJMXOEYIERK-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000026731 phosphorylation Effects 0.000 description 6
- 238000006366 phosphorylation reaction Methods 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- OAGVGSFXLRIMDW-UHFFFAOYSA-N 2-[(2-methoxy-5-nitrophenyl)methylsulfonyl]acetic acid Chemical compound COC1=CC=C([N+]([O-])=O)C=C1CS(=O)(=O)CC(O)=O OAGVGSFXLRIMDW-UHFFFAOYSA-N 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000007911 parenteral administration Methods 0.000 description 5
- WXSGQHKHUYTJNB-UHFFFAOYSA-N 2,6-dimethoxybenzaldehyde Chemical compound COC1=CC=CC(OC)=C1C=O WXSGQHKHUYTJNB-UHFFFAOYSA-N 0.000 description 4
- VMYFZBLZKJJKLR-UHFFFAOYSA-N 2-[(4-bromophenyl)methylsulfonyl]acetic acid Chemical compound OC(=O)CS(=O)(=O)CC1=CC=C(Br)C=C1 VMYFZBLZKJJKLR-UHFFFAOYSA-N 0.000 description 4
- JZLMLFCJWFMZMC-UHFFFAOYSA-N 3-phenylpropanethioic s-acid Chemical compound SC(=O)CCC1=CC=CC=C1 JZLMLFCJWFMZMC-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 4
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- YYXBXAYHHCTPEF-UHFFFAOYSA-N 2-[(4-chlorophenyl)methylsulfonyl]acetic acid Chemical compound OC(=O)CS(=O)(=O)CC1=CC=C(Cl)C=C1 YYXBXAYHHCTPEF-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 230000002962 histologic effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 2
- JIVGSHFYXPRRSZ-UHFFFAOYSA-N 2,3-dimethoxybenzaldehyde Chemical compound COC1=CC=CC(C=O)=C1OC JIVGSHFYXPRRSZ-UHFFFAOYSA-N 0.000 description 2
- IGHOQZIXSOUKCP-UHFFFAOYSA-N 2-[(2,4-dichlorophenyl)methylsulfonyl]acetic acid Chemical compound OC(=O)CS(=O)(=O)CC1=CC=C(Cl)C=C1Cl IGHOQZIXSOUKCP-UHFFFAOYSA-N 0.000 description 2
- RIEVRVHUHDULFT-UHFFFAOYSA-N 2-[(2,6-dimethoxyphenyl)methylsulfonyl]acetic acid Chemical compound COC1=CC=CC(OC)=C1CS(=O)(=O)CC(O)=O RIEVRVHUHDULFT-UHFFFAOYSA-N 0.000 description 2
- CDAPTSRXGQRZMQ-UHFFFAOYSA-N 2-[(4-nitrophenyl)methylsulfonyl]acetic acid Chemical compound OC(=O)CS(=O)(=O)CC1=CC=C([N+]([O-])=O)C=C1 CDAPTSRXGQRZMQ-UHFFFAOYSA-N 0.000 description 2
- VFZRZRDOXPRTSC-UHFFFAOYSA-N 3,5-Dimethoxybenzaldehyde Chemical compound COC1=CC(OC)=CC(C=O)=C1 VFZRZRDOXPRTSC-UHFFFAOYSA-N 0.000 description 2
- NALVGTOMKSKFFV-UHFFFAOYSA-N 4-fluoro-3-methoxybenzaldehyde Chemical compound COC1=CC(C=O)=CC=C1F NALVGTOMKSKFFV-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 230000004668 G2/M phase Effects 0.000 description 2
- 238000006000 Knoevenagel condensation reaction Methods 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 2
- 108700015928 Mitogen-activated protein kinase 13 Proteins 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- WHBMMWSBFZVSSR-UHFFFAOYSA-N R3HBA Natural products CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 229940073608 benzyl chloride Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000865 phosphorylative effect Effects 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 125000005504 styryl group Chemical group 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- WJUFSDZVCOTFON-UHFFFAOYSA-N veratraldehyde Chemical compound COC1=CC=C(C=O)C=C1OC WJUFSDZVCOTFON-UHFFFAOYSA-N 0.000 description 2
- XDIYNQZUNSSENW-UUBOPVPUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-UUBOPVPUSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- MAUMSNABMVEOGP-UHFFFAOYSA-N (methyl-$l^{2}-azanyl)methane Chemical compound C[N]C MAUMSNABMVEOGP-UHFFFAOYSA-N 0.000 description 1
- 0 *c1ccc(CS(C=Cc2ccccc2)(=O)=O)cc1 Chemical compound *c1ccc(CS(C=Cc2ccccc2)(=O)=O)cc1 0.000 description 1
- IGHDRKYVYSDMIJ-GJHDBBOXSA-N 1-[(e)-3-[(e)-3-(2,3-dimethoxyphenyl)-1-(4-methoxyphenyl)prop-2-enyl]sulfonyl-3-(4-methoxyphenyl)prop-1-enyl]-2,3-dimethoxybenzene Chemical compound C1=CC(OC)=CC=C1C(S(=O)(=O)C(\C=C\C=1C(=C(OC)C=CC=1)OC)C=1C=CC(OC)=CC=1)\C=C\C1=CC=CC(OC)=C1OC IGHDRKYVYSDMIJ-GJHDBBOXSA-N 0.000 description 1
- LEJNQVPPDCLKOC-RPCRKUJJSA-N 1-[(e)-3-[(e)-3-(2,4-diethoxyphenyl)-1-(4-methoxyphenyl)prop-2-enyl]sulfonyl-3-(4-methoxyphenyl)prop-1-enyl]-2,4-diethoxybenzene Chemical compound CCOC1=CC(OCC)=CC=C1\C=C\C(S(=O)(=O)C(\C=C\C=1C(=CC(OCC)=CC=1)OCC)C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 LEJNQVPPDCLKOC-RPCRKUJJSA-N 0.000 description 1
- QXQAPNSHUJORMC-UHFFFAOYSA-N 1-chloro-4-propylbenzene Chemical compound CCCC1=CC=C(Cl)C=C1 QXQAPNSHUJORMC-UHFFFAOYSA-N 0.000 description 1
- PSYRWFPOGADSEW-YHARCJFQSA-N 1-methoxy-3-[(e)-3-[(e)-3-(3-methoxy-2-nitrophenyl)-1-(4-methoxyphenyl)prop-2-enyl]sulfonyl-3-(4-methoxyphenyl)prop-1-enyl]-2-nitrobenzene Chemical compound C1=CC(OC)=CC=C1C(S(=O)(=O)C(\C=C\C=1C(=C(OC)C=CC=1)[N+]([O-])=O)C=1C=CC(OC)=CC=1)\C=C\C1=CC=CC(OC)=C1[N+]([O-])=O PSYRWFPOGADSEW-YHARCJFQSA-N 0.000 description 1
- JGWAODQUCDFPGI-UHFFFAOYSA-N 2,4-diethoxybenzaldehyde Chemical compound CCOC1=CC=C(C=O)C(OCC)=C1 JGWAODQUCDFPGI-UHFFFAOYSA-N 0.000 description 1
- UGNJILDLOHTRMK-UHFFFAOYSA-N 2,5-diethoxybenzaldehyde Chemical compound CCOC1=CC=C(OCC)C(C=O)=C1 UGNJILDLOHTRMK-UHFFFAOYSA-N 0.000 description 1
- AFUKNJHPZAVHGQ-UHFFFAOYSA-N 2,5-dimethoxy-Benzaldehyde Chemical compound COC1=CC=C(OC)C(C=O)=C1 AFUKNJHPZAVHGQ-UHFFFAOYSA-N 0.000 description 1
- OYUBAPFRCZGIEH-UHFFFAOYSA-N 2-[(2-methoxyphenyl)methylsulfonyl]acetic acid Chemical compound COC1=CC=CC=C1CS(=O)(=O)CC(O)=O OYUBAPFRCZGIEH-UHFFFAOYSA-N 0.000 description 1
- STQLDAZMDJUSKV-UHFFFAOYSA-N 2-[(4-fluorophenyl)methylsulfonyl]acetic acid Chemical compound OC(=O)CS(=O)(=O)CC1=CC=C(F)C=C1 STQLDAZMDJUSKV-UHFFFAOYSA-N 0.000 description 1
- XUALPJBVAXYDOV-MBALSZOMSA-N 2-[(e)-1-[(e)-1-(2,6-dimethoxyphenyl)-3-(2-methoxyphenyl)prop-2-enyl]sulfonyl-3-(2-methoxyphenyl)prop-2-enyl]-1,3-dimethoxybenzene Chemical compound COC1=CC=CC=C1\C=C\C(S(=O)(=O)C(\C=C\C=1C(=CC=CC=1)OC)C=1C(=CC=CC=1OC)OC)C1=C(OC)C=CC=C1OC XUALPJBVAXYDOV-MBALSZOMSA-N 0.000 description 1
- YMXKMZCMOZWNOK-YHARCJFQSA-N 2-[(e)-1-[(e)-1-(2,6-dimethoxyphenyl)-3-(4-fluorophenyl)prop-2-enyl]sulfonyl-3-(4-fluorophenyl)prop-2-enyl]-1,3-dimethoxybenzene Chemical compound COC1=CC=CC(OC)=C1C(S(=O)(=O)C(\C=C\C=1C=CC(F)=CC=1)C=1C(=CC=CC=1OC)OC)\C=C\C1=CC=C(F)C=C1 YMXKMZCMOZWNOK-YHARCJFQSA-N 0.000 description 1
- CVEQNZGDWDYUSP-FLFKKZLDSA-N 2-[(e)-3-(4-bromophenyl)-3-[(e)-1-(4-bromophenyl)-3-(2,6-dimethoxyphenyl)prop-2-enyl]sulfonylprop-1-enyl]-1,3-dimethoxybenzene Chemical compound COC1=CC=CC(OC)=C1\C=C\C(S(=O)(=O)C(\C=C\C=1C(=CC=CC=1OC)OC)C=1C=CC(Br)=CC=1)C1=CC=C(Br)C=C1 CVEQNZGDWDYUSP-FLFKKZLDSA-N 0.000 description 1
- FZLQXXRXDZHVFV-FLFKKZLDSA-N 2-[(e)-3-(4-chlorophenyl)-3-[(e)-1-(4-chlorophenyl)-3-(2,6-dimethoxyphenyl)prop-2-enyl]sulfonylprop-1-enyl]-1,3-dimethoxybenzene Chemical compound COC1=CC=CC(OC)=C1\C=C\C(S(=O)(=O)C(\C=C\C=1C(=CC=CC=1OC)OC)C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 FZLQXXRXDZHVFV-FLFKKZLDSA-N 0.000 description 1
- FRGDNZRHWONDRK-RYQLWAFASA-N 2-[(e)-3-[(e)-3-(2,5-diethoxyphenyl)-1-(4-methoxyphenyl)prop-2-enyl]sulfonyl-3-(4-methoxyphenyl)prop-1-enyl]-1,4-diethoxybenzene Chemical compound CCOC1=CC=C(OCC)C(\C=C\C(C=2C=CC(OC)=CC=2)S(=O)(=O)C(\C=C\C=2C(=CC=C(OCC)C=2)OCC)C=2C=CC(OC)=CC=2)=C1 FRGDNZRHWONDRK-RYQLWAFASA-N 0.000 description 1
- AWRWZQGPIQDPDO-FLFKKZLDSA-N 2-[(e)-3-[(e)-3-(2,6-dimethoxyphenyl)-1-(4-nitrophenyl)prop-2-enyl]sulfonyl-3-(4-nitrophenyl)prop-1-enyl]-1,3-dimethoxybenzene Chemical compound COC1=CC=CC(OC)=C1\C=C\C(S(=O)(=O)C(\C=C\C=1C(=CC=CC=1OC)OC)C=1C=CC(=CC=1)[N+]([O-])=O)C1=CC=C([N+]([O-])=O)C=C1 AWRWZQGPIQDPDO-FLFKKZLDSA-N 0.000 description 1
- LFRNRTSKPHWZNN-IAGONARPSA-N 2-[(e)-3-[(e)-3-(2-amino-5-chlorophenyl)-1-(4-bromophenyl)prop-2-enyl]sulfonyl-3-(4-bromophenyl)prop-1-enyl]-4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1\C=C\C(S(=O)(=O)C(\C=C\C=1C(=CC=C(Cl)C=1)N)C=1C=CC(Br)=CC=1)C1=CC=C(Br)C=C1 LFRNRTSKPHWZNN-IAGONARPSA-N 0.000 description 1
- RHJPVRAMDCUBJS-IAGONARPSA-N 2-[(e)-3-[(e)-3-(2-amino-5-chlorophenyl)-1-(4-chlorophenyl)prop-2-enyl]sulfonyl-3-(4-chlorophenyl)prop-1-enyl]-4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1\C=C\C(S(=O)(=O)C(\C=C\C=1C(=CC=C(Cl)C=1)N)C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 RHJPVRAMDCUBJS-IAGONARPSA-N 0.000 description 1
- LRSBJYVMTLPHGW-IAGONARPSA-N 2-[(e)-3-[(e)-3-(2-amino-5-chlorophenyl)-1-(4-fluorophenyl)prop-2-enyl]sulfonyl-3-(4-fluorophenyl)prop-1-enyl]-4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1\C=C\C(S(=O)(=O)C(\C=C\C=1C(=CC=C(Cl)C=1)N)C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 LRSBJYVMTLPHGW-IAGONARPSA-N 0.000 description 1
- WFUWOQJLKFITMO-ZEELXFFVSA-N 2-[(e)-3-[(e)-3-(2-amino-5-chlorophenyl)-1-(4-methoxyphenyl)prop-2-enyl]sulfonyl-3-(4-methoxyphenyl)prop-1-enyl]-4-chloroaniline Chemical compound C1=CC(OC)=CC=C1C(S(=O)(=O)C(\C=C\C=1C(=CC=C(Cl)C=1)N)C=1C=CC(OC)=CC=1)\C=C\C1=CC(Cl)=CC=C1N WFUWOQJLKFITMO-ZEELXFFVSA-N 0.000 description 1
- IZFOKURKXQRYNA-IAGONARPSA-N 2-[(e)-3-[(e)-3-(2-amino-5-chlorophenyl)-1-(4-nitrophenyl)prop-2-enyl]sulfonyl-3-(4-nitrophenyl)prop-1-enyl]-4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1\C=C\C(S(=O)(=O)C(\C=C\C=1C(=CC=C(Cl)C=1)N)C=1C=CC(=CC=1)[N+]([O-])=O)C1=CC=C([N+]([O-])=O)C=C1 IZFOKURKXQRYNA-IAGONARPSA-N 0.000 description 1
- KUIFMGITZFDQMP-UHFFFAOYSA-N 2-amino-5-chlorobenzaldehyde Chemical compound NC1=CC=C(Cl)C=C1C=O KUIFMGITZFDQMP-UHFFFAOYSA-N 0.000 description 1
- RSKWTLORDFSRPV-VGENTYGXSA-N 2-ethoxy-4-[(e)-3-[(e)-3-(3-ethoxy-4-hydroxyphenyl)-1-(4-methoxyphenyl)prop-2-enyl]sulfonyl-3-(4-methoxyphenyl)prop-1-enyl]phenol Chemical compound C1=C(O)C(OCC)=CC(\C=C\C(C=2C=CC(OC)=CC=2)S(=O)(=O)C(\C=C\C=2C=C(OCC)C(O)=CC=2)C=2C=CC(OC)=CC=2)=C1 RSKWTLORDFSRPV-VGENTYGXSA-N 0.000 description 1
- PQGRDBDRGPKZLT-GJHDBBOXSA-N 2-ethoxy-6-[(e)-3-[(e)-3-(3-ethoxy-2-hydroxyphenyl)-1-(4-methoxyphenyl)prop-2-enyl]sulfonyl-3-(4-methoxyphenyl)prop-1-enyl]phenol Chemical compound CCOC1=CC=CC(\C=C\C(C=2C=CC(OC)=CC=2)S(=O)(=O)C(\C=C\C=2C(=C(OCC)C=CC=2)O)C=2C=CC(OC)=CC=2)=C1O PQGRDBDRGPKZLT-GJHDBBOXSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- AUBBVPIQUDFRQI-UHFFFAOYSA-N 3-hydroxy-4-nitrobenzaldehyde Chemical compound OC1=CC(C=O)=CC=C1[N+]([O-])=O AUBBVPIQUDFRQI-UHFFFAOYSA-N 0.000 description 1
- GDTUACILWWLIJF-UHFFFAOYSA-N 3-methoxy-2-nitrobenzaldehyde Chemical compound COC1=CC=CC(C=O)=C1[N+]([O-])=O GDTUACILWWLIJF-UHFFFAOYSA-N 0.000 description 1
- ZETIVVHRRQLWFW-UHFFFAOYSA-N 3-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=CC(C=O)=C1 ZETIVVHRRQLWFW-UHFFFAOYSA-N 0.000 description 1
- PHRVSYKBPOCVMP-QJZPKIEXSA-N 4-[(e)-3-(4-bromophenyl)-3-[(e)-1-(4-bromophenyl)-3-(4-fluoro-3-methoxyphenyl)prop-2-enyl]sulfonylprop-1-enyl]-1-fluoro-2-methoxybenzene Chemical compound C1=C(F)C(OC)=CC(\C=C\C(C=2C=CC(Br)=CC=2)S(=O)(=O)C(\C=C\C=2C=C(OC)C(F)=CC=2)C=2C=CC(Br)=CC=2)=C1 PHRVSYKBPOCVMP-QJZPKIEXSA-N 0.000 description 1
- IAKDZNOJUNQULJ-QJZPKIEXSA-N 4-[(e)-3-(4-chlorophenyl)-3-[(e)-1-(4-chlorophenyl)-3-(4-fluoro-3-methylphenyl)prop-2-enyl]sulfonylprop-1-enyl]-1-fluoro-2-methylbenzene Chemical compound C1=C(F)C(C)=CC(\C=C\C(C=2C=CC(Cl)=CC=2)S(=O)(=O)C(\C=C\C=2C=C(C)C(F)=CC=2)C=2C=CC(Cl)=CC=2)=C1 IAKDZNOJUNQULJ-QJZPKIEXSA-N 0.000 description 1
- AVPYQKSLYISFPO-UHFFFAOYSA-N 4-chlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C=C1 AVPYQKSLYISFPO-UHFFFAOYSA-N 0.000 description 1
- DOULGHINSFURSM-UHFFFAOYSA-N 4-fluoro-3-hydroxybenzaldehyde Chemical compound OC1=CC(C=O)=CC=C1F DOULGHINSFURSM-UHFFFAOYSA-N 0.000 description 1
- UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 description 1
- 125000005274 4-hydroxybenzoic acid group Chemical group 0.000 description 1
- BXRFQSNOROATLV-UHFFFAOYSA-N 4-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=C(C=O)C=C1 BXRFQSNOROATLV-UHFFFAOYSA-N 0.000 description 1
- ZQEITCPFGDURIR-FDOALMFVSA-N 5-[(e)-3-(4-bromophenyl)-3-[(e)-1-(4-bromophenyl)-3-(4-fluoro-3-hydroxyphenyl)prop-2-enyl]sulfonylprop-1-enyl]-2-fluorophenol Chemical compound C1=C(F)C(O)=CC(\C=C\C(C=2C=CC(Br)=CC=2)S(=O)(=O)C(\C=C\C=2C=C(O)C(F)=CC=2)C=2C=CC(Br)=CC=2)=C1 ZQEITCPFGDURIR-FDOALMFVSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 101100397594 Ancylostoma caninum JNK-1 gene Proteins 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108030004793 Dual-specificity kinases Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108700027649 Mitogen-Activated Protein Kinase 3 Proteins 0.000 description 1
- 102100024192 Mitogen-activated protein kinase 3 Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108010016131 Proto-Oncogene Proteins c-jun Proteins 0.000 description 1
- 102000000427 Proto-Oncogene Proteins c-jun Human genes 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 229910006074 SO2NH2 Inorganic materials 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Natural products OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- LKEKWDJCJSPXNI-IRIUXVKKSA-N Thr-Glu-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 LKEKWDJCJSPXNI-IRIUXVKKSA-N 0.000 description 1
- YGZWVPBHYABGLT-KJEVXHAQSA-N Thr-Pro-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 YGZWVPBHYABGLT-KJEVXHAQSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 150000005524 benzylchlorides Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 230000001672 cytoproliferative effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 125000002474 dimethylaminoethoxy group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])O* 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003499 exocrine gland Anatomy 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 125000000394 phosphonato group Chemical group [O-]P([O-])(*)=O 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- GNBVPFITFYNRCN-UHFFFAOYSA-M sodium thioglycolate Chemical compound [Na+].[O-]C(=O)CS GNBVPFITFYNRCN-UHFFFAOYSA-M 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000003699 striated muscle Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000010304 tumor cell viability Effects 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/18—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/02—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms
- C07C317/10—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23822200P | 2000-10-05 | 2000-10-05 | |
| US60/238,222 | 2000-10-05 | ||
| PCT/US2001/031337 WO2002028828A1 (en) | 2000-10-05 | 2001-10-05 | Substituted (e)-styryl benzylsulfones for treating proliferative disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2424884A1 CA2424884A1 (en) | 2002-04-11 |
| CA2424884C true CA2424884C (en) | 2009-12-15 |
Family
ID=22896982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002424884A Expired - Fee Related CA2424884C (en) | 2000-10-05 | 2001-10-05 | Substituted (e)-styryl benzylsulfones for treating proliferative disorders |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7053123B2 (https=) |
| EP (1) | EP1328511B1 (https=) |
| JP (1) | JP2004510761A (https=) |
| AT (1) | ATE461915T1 (https=) |
| AU (1) | AU2001296677A1 (https=) |
| CA (1) | CA2424884C (https=) |
| DE (1) | DE60141641D1 (https=) |
| WO (1) | WO2002028828A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6548553B2 (en) * | 1997-10-03 | 2003-04-15 | Temple University-Of The Commonwealth System Of Higher Education | Styryl sulfone anticancer agents |
| US6767926B1 (en) * | 1999-10-12 | 2004-07-27 | Temple University - Of The Commonwealth System Of Higher Education | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents |
| EP1534284B1 (en) * | 2002-02-28 | 2011-07-27 | Temple University - Of The Commonwealth System of Higher Education | Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders |
| NZ535232A (en) * | 2002-02-28 | 2007-05-31 | Univ Temple | Amino-substituted (E)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders |
| WO2005046599A2 (en) * | 2003-11-14 | 2005-05-26 | Temple University - Of The Commonwealth System Of Higher Education | Alpha, beta-unsaturated sulfoxides for treating proliferative disorders |
| NZ549962A (en) | 2004-03-16 | 2010-04-30 | Univ Temple | Substituted phenoxy-and phenylthio-derivatives for treating proliferative disorders |
| US8058313B2 (en) | 2004-06-24 | 2011-11-15 | Temple University—Of the Commonwealth System of Higher Education | Alpha, beta-unsaturated sulfones, sulfoxides, sulfonimides, sulfinimides, acylsulfonamides and acylsulfinamides and therapeutic uses thereof |
| JP5278968B2 (ja) | 2006-08-30 | 2013-09-04 | テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション | 骨髄異形性症候群及び急性骨髄性白血病の治療のための組成物及び方法 |
| AU2013318206B2 (en) | 2012-09-20 | 2018-07-26 | Temple University - Of The Commonwealth System Of Higher Education | Substituted alkyl diaryl derivatives, methods of preparation and uses |
| WO2014089483A1 (en) | 2012-12-07 | 2014-06-12 | Onconova Therapeutics, Inc. | Methods and compositions for treatment of cancer |
| US10383831B2 (en) | 2015-08-03 | 2019-08-20 | Temple University—Of the Commonwealth System of Higher Education | 2,4,6-trialkoxystryl aryl sulfones, sulfonamides and carboxamides, and methods of preparation and use |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2532612A (en) | 1945-08-29 | 1950-12-05 | Union Oil Co | Preparation of unsaturated thio-ethers |
| US3185743A (en) | 1960-08-24 | 1965-05-25 | Union Carbide Corp | Production of olefinic compounds from allyl sulfones |
| US3463774A (en) | 1963-03-18 | 1969-08-26 | Hoffmann La Roche | Novel 4,1-benzothiazepin-2-(1h)-ones and 4,1-benzothiazepines |
| US3418101A (en) | 1965-12-15 | 1968-12-24 | Pennsalt Chemicals Corp | Process for plant desiccation |
| US3514386A (en) | 1967-12-11 | 1970-05-26 | Exxon Research Engineering Co | Stereoselective addition of thiols to acetylenic compounds |
| US3917714A (en) | 1972-09-06 | 1975-11-04 | American Cyanamid Co | Bis(alkylsulfonyl)vinylbenzenes |
| US4161407A (en) | 1977-10-06 | 1979-07-17 | Eastman Kodak Company | Crosslinkable polymers having vinylsulfonyl groups or styrylsulfonyl groups and their use as hardeners for gelatin |
| US4386221A (en) | 1981-10-28 | 1983-05-31 | Eastman Kodak Company | Process for the preparation of aryl alkyl sulfones and aryl vinyl sulfones |
| US4937388A (en) | 1985-08-09 | 1990-06-26 | Imperial Chemical Industries Plc | Insecticidal ethers |
| US5659087A (en) | 1995-06-07 | 1997-08-19 | Eli Lilly And Company | Diarylvinyl sulfoxides |
| US5733909A (en) | 1996-02-01 | 1998-03-31 | Merck Frosst Canada, Inc. | Diphenyl stilbenes as prodrugs to COX-2 inhibitors |
| US6030961A (en) * | 1997-03-11 | 2000-02-29 | Bar-Ilan Research & Development Co., Ltd. | Oxyalkylene phosphate compounds and uses thereof |
| CN1163480C (zh) | 1997-10-03 | 2004-08-25 | 坦普尔大学 | 苯乙烯砜抗癌剂 |
| US6548553B2 (en) | 1997-10-03 | 2003-04-15 | Temple University-Of The Commonwealth System Of Higher Education | Styryl sulfone anticancer agents |
| US6201154B1 (en) | 1999-03-31 | 2001-03-13 | Temple University-Of The Commonwealth Of Higher Education | Z-styryl sulfone anticancer agents |
| US6762207B1 (en) * | 1999-04-02 | 2004-07-13 | Temple University - Of The Commonwealth System Of Higher Education | (E)-styryl sulfone anticancer agents |
| US6418101B1 (en) * | 1999-09-03 | 2002-07-09 | Zen Research (Ireland), Ltd. | Digital read channel for optical disk reader |
| US6767926B1 (en) * | 1999-10-12 | 2004-07-27 | Temple University - Of The Commonwealth System Of Higher Education | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents |
| WO2001026645A1 (en) | 1999-10-12 | 2001-04-19 | Temple University-Of The Commonwealth System Of Higher Education | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents |
| US6486210B2 (en) | 2000-04-14 | 2002-11-26 | Temple University—Of the Commonwealth System of Higher Education | Substituted styryl benzylsulfones for treating proliferative disorders |
| US6541475B2 (en) * | 2000-04-14 | 2003-04-01 | Temple University - Of The Commonwealth System Of Higher Education | α, β-unsaturated sulfones for treating proliferative disorders |
| WO2002069892A2 (en) | 2001-02-28 | 2002-09-12 | Temple University Of The Commonwealth System Of Higher Education | METHOD FOR PROTECTING CELLS AND TISSUES FROM IONIZING RADIATION TOXICITY WITH α, β UNSATURATED ARYL SULFONES |
-
2001
- 2001-10-05 AU AU2001296677A patent/AU2001296677A1/en not_active Abandoned
- 2001-10-05 WO PCT/US2001/031337 patent/WO2002028828A1/en not_active Ceased
- 2001-10-05 DE DE60141641T patent/DE60141641D1/de not_active Expired - Lifetime
- 2001-10-05 JP JP2002532414A patent/JP2004510761A/ja active Pending
- 2001-10-05 AT AT01977567T patent/ATE461915T1/de not_active IP Right Cessation
- 2001-10-05 US US10/398,545 patent/US7053123B2/en not_active Expired - Fee Related
- 2001-10-05 CA CA002424884A patent/CA2424884C/en not_active Expired - Fee Related
- 2001-10-05 EP EP01977567A patent/EP1328511B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002028828A1 (en) | 2002-04-11 |
| EP1328511A1 (en) | 2003-07-23 |
| DE60141641D1 (de) | 2010-05-06 |
| US7053123B2 (en) | 2006-05-30 |
| EP1328511A4 (en) | 2005-11-30 |
| US20050101528A1 (en) | 2005-05-12 |
| JP2004510761A (ja) | 2004-04-08 |
| AU2001296677A1 (en) | 2002-04-15 |
| EP1328511B1 (en) | 2010-03-24 |
| ATE461915T1 (de) | 2010-04-15 |
| CA2424884A1 (en) | 2002-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6486210B2 (en) | Substituted styryl benzylsulfones for treating proliferative disorders | |
| AU2001251615A1 (en) | Substituted styryl benzylsulfones for treating proliferative disorders | |
| US6762207B1 (en) | (E)-styryl sulfone anticancer agents | |
| CA2424884C (en) | Substituted (e)-styryl benzylsulfones for treating proliferative disorders | |
| JP4468593B2 (ja) | Ｚ−スチリルスルホン抗癌剤 | |
| EP1173160B1 (en) | (e)-styryl sulfone anticancer agents | |
| US6833480B2 (en) | (Z)-styrylbenzylsulfones and pharmaceutical uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20181005 |